Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.
In tissue culture, efficacy against either murine CMV or HSV-2 was increased 27-fold for the acyclic nucleoside ganciclovir and 3-fold for foscarnet (trisodium phosphonoformate) when the 2 drugs were combined; whereas against human CMV, efficacy was increased 3-fold for both drugs. In mice, efficacy was increased 2-fold for ganciclovir and 4- to 5-fold for foscarnet when used in combination against either murine CMV or HSV-2. These results suggest an additive interaction between the two drugs in vivo.
Freitas
V R
VR
Syntex Research, Palo Alto, CA 94304.
Fraser-Smith
E B
EB
Matthews
T R
TR
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival; D003587:Cytomegalovirus / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D017245:Foscarnet; D015774:Ganciclovir / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D010746:Phosphonoacetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D018139:Simplexvirus / Q000187:drug effects*; D010948:Viral Plaque Assay
D000998:Antiviral Agents; D017245:Foscarnet; D010746:Phosphonoacetic Acid; D015774:Ganciclovir